Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4752-4755

  Meyers, Ross O ^a   Lambert, Joshua D ^b   Hajicek, Nicole ^c   Pourpak, Alan ^a   Kalaitzis, John A ^d   Dorr, Robert T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Analogs; Cancer; Melanoma; NDGA; Nordihydroguaiaretic acid

Indexed keywords

METHYLENEDIOXYPHENYLNORDIHYDROGUAIARETIC ACID; NORDIHYDROGUAIARETIC ACID; NORDIHYDROGUAIARETIC ACID BISCYCLIC CARBONATE; NORDIHYDROGUAIARETIC ACID BISCYCLIC SULFATE; NORDIHYDROGUAIARETIC ACID TETRAACETATE; PHENOL; TETRA O METHYLNORDIHYDROGUAIARETIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DERIVATIZATION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MELANOMA; MICE; NORDIHYDROGUAIARETIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

TETRA;

EID: 67651124984     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.063     Document Type: Article

References (25)

1. Tyler V.E. The Honest Herbal a Sensible Guide to the Use of Herbs and Related Remedies (1994), Pharmaceutical Products Press, New York
2. Van der Zee J., Eling T.E., and Mason R.P. Biochemistry 28 (1989) 8363
3. Whitman S., Gezginci M., Timmermann B.N., and Holman T.R. J. Med. Chem. 45 (2002) 2659
4. Sndyer D.S., Castro R., and Desforges J.F. Exp. Hematol. 17 (1989) 6
5. Avis I.M., Jett M., Boyle T., Vos M.D., Moody T., Treston A.M., Martinez A., and Mulshine J.L. J. Clin. Invest. 97 (1996) 806
6. Moody T.W., Leyton J., Martinez A., Hong S., Malkinson A., and Mulshine J.L. Exp. Lung Res. 24 (1998) 617
7. Seufferlein T., Secki M.J., Schwarz E., Beil M., Wichert G.v., Baust H., Lührs H., Schmid R.M., and Adler G. Br. J. Cancer 86 (2002) 1188
8. Chen X., Li N., Hong J., Fang M., Yousselfson J., Yang P., Newman R.A., Lubet R.A., and Yang C.S. Carcinogenesis 23 (2002) 2095
9. Gnabre J.N., Brady J.N., Clanton D.J., Ito Y., Dittmer J., Bates R.B., and Huang R.C.C. Proc. Natl. Acad. Sci. 92 (1995) 11239
10. Gnabre J., Huang R.C.C., Bates R.B., Burns J.J., Caldera S., Malconson M.E., and McClure K.J. Tetrahedron 51 (1995) 12203
11. Hwu J.R., Tseng W.N., Gnabre J., Giza P., and Huang R.C. J. Med. Chem. 41 (1998) 2990
12. Chen H., Teng L., Li J.-N., Park R., Mold D.E., Gnabre J., and Hwu J.R. J. Med. Chem. 41 (1998) 3001
13. Craigo J., Callahan M., Huang R.C.C., and DeLucia A.L. Antiviral Res. 7 (2000) 19
14. Huang R.C.C., Li Y., Giza P.E., Gnabre J.N., Abd-Elazem I.S., King K.Y., and Hwu J.R. Antiviral Res. 58 (2003) 57
15. Park R., Giza R.E., Mold D.E., and Huang R.C.C. Antiviral Res. 58 (2003) 35
16. Hwu J.R., Hsu M.-H., and Huang R.C. Bioorg. Med. Chem. Lett. 18 (2008) 1884
17. Heller J.D., Kuo J., Wu T.C., Kast W.M., and Huang R.C.C. Cancer Res. 61 (2001) 5499
18. Chang C.-C., Heller J.D., Kuo J., and Huang R.C.C. PNAS 101 (2004) 13239
19. Park R., Chang C.-C., Liang Y.-C., Chung Y., Henry R.A., Lin E., Mold D.E., and Huang R.C.C. Clin. Cancer Res. 11 (2005) 4601
20. Lambert J.D., Meyers R.O., Timmerman B.N., and Dorr R.T. Cancer Lett. 171 (2001) 47
21. Lambert J.D., Zhao D., Meyers R.O., Kuester R.K., Timmermann B.N., and Dorr R.T. Toxicon 40 (2002) 1701
22. Tickner A.M., Liu C., Hild E., and Mendelson W. Synth. Commun. 24 (1994) 1631
23. Grazia M., Enzo C., De Montis S., Fattuoni C., Melis S., and Usai M. Tetrahedron 59 (2003) 4383
24. Mayr C.A., Sami S.M., and Dorr R.T. Anti-Cancer Drugs 8 (1997) 245
25. Bissery M.-C., Guénard D., Guéritte Veogelein F., and Lavelle F. Cancer Res. 51 (1991) 4845 According to NCI standards, a T/C ≤ 42% is the minimum level for activity. A T/C < 10% is considered as a high antitimor activity level which justifies further development (DN-2 level)